EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Why BofA says July Fed rate hike would be "unprecedented"
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Edwards Lifesciences (EW) PT Lowered to $85 at Truist Securities
December 9, 2022 7:32 AM ESTTruist Securities analyst Richard Newitter lowered the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $95.00) while maintaining a Buy rating.
The analyst commented, "While a planned CEO transition does add a new factor, EW's NYC I-Day is unlikely to sway the... More
